商保创新药药房遇冷，这些进口药院内渗透快

Core Viewpoint - The article discusses the implementation and sales performance of the newly established commercial insurance innovative drug directory, highlighting the concentration of sales in major cities and the challenges faced in expanding access to these drugs across the country [3][7]. Summary by Sections Sales Performance of New Drug Directories - As of January 20, 2026, 99 new drugs from the basic medical insurance directory have been sold in 12,198 designated medical institutions, while 14 drugs from the commercial insurance innovative drug directory have been sold in 223 institutions [3][4]. - Over 70% of the commercial insurance innovative drugs have recorded sales, with Alzheimer's disease treatments showing the highest penetration in the hospital market [4][5]. Specific Drug Sales Insights - The drug Lecanemab, developed by Eisai, has been sold in 158 institutions, while Eli Lilly's Donanemab has been recorded in 46 institutions [4]. - The number of patients with mild cognitive impairment or mild dementia due to Alzheimer's disease in China is projected to reach 17 million by 2024, indicating a broad patient base for these treatments [5]. Challenges in Rare Disease Drug Sales - Rare disease drugs face challenges due to their limited patient populations and the concentration of prescriptions in specialized hospitals, resulting in sparse sales data [5][6]. - For instance, Takeda's drug for short bowel syndrome has only been sold in one designated pharmacy in Shenzhen this year [5]. Market Access and Policy Implications - Five innovative drugs have yet to achieve sales in designated medical institutions, including CAR-T products priced between 990,000 to 1.3 million yuan per injection [6]. - The National Healthcare Security Administration has implemented a "three exclusions" policy to facilitate the entry of high-cost drugs into hospitals, but the transition from "entry" to "sales" remains complex due to various factors [6][7]. Regional Disparities in Sales - Sales of commercial insurance innovative drugs are still concentrated in major provinces like Beijing, Shanghai, Jiangsu, and Guangdong, with retail pharmacies accounting for less than 10% of sales [7][8]. - Some regions, such as Guangdong and Chongqing, have begun to support the prescription flow of commercial insurance innovative drugs, but broader implementation is needed [8].